Biodesix, Inc.
Biodesix, Inc. (Nasdaq: BDSX) is a diagnostic solutions company that develops and provides blood-based tests for lung disease and diagnostic development services for biopharmaceutical, life sciences, and research organizations. Its Lung Diagnostic Testing business offers five tests to help healthcare providers assess… From the company’s description.
Over the twelve months to Sep 30, 2026, Biodesix, Inc. reported revenue of $105.21M, up 31.2% from a year earlier, and a net loss of $27.08M. Its operating margin was −18.7%, and operations used $18.16M in cash. In fiscal 2025, it reported revenue of $88.50M, up 24.1% from fiscal 2024, and a net loss of $35.27M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Biodesix, Inc. does
In the company’s own words
Biodesix, Inc. (Nasdaq: BDSX) is a diagnostic solutions company that develops and provides blood-based tests for lung disease and diagnostic development services for biopharmaceutical, life sciences, and research organizations. Its Lung Diagnostic Testing business offers five tests to help healthcare providers assess cancer risk in lung nodules and guide treatment and monitoring for non-small cell lung cancer. The tests include the Nodify Lung nodule assessment products and the IQLung portfolio, which combines VeriStrat immune profiling with GeneStrat tumor profiling. Development Services provides research, biomarker discovery, assay development and validation, clinical-trial testing, and regulatory, reimbursement, commercialization, and logistics support. The company serves healthcare providers and patients through its testing services, and biopharmaceutical, life sciences, diagnostic, and academic research customers through development work. In 2025, Lung Diagnostic Testing generated $79.2 million of revenue and Development Services generated $9.3 million; total revenue was approximately $88.5 million. Biodesix’s branded tests include Nodify Lung, VeriStrat, and GeneStrat. Its website is www.biodesix.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- LOUISVILLE, CO
- Fiscal year end
- December
- CIK
- 1439725
- SIC
- 8071
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Biodesix, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Biodesix, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Biodesix, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Biodesix, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Biodesix, Inc.'s last four quarterly filings that the numbers alone won't show?”